• +1-646-491-9876
    • +91-20-67278686

    Search

    Mumps - Pipeline Review, H1 2017

    Mumps - Pipeline Review, H1 2017

    • Report Code ID: RW0001689455
    • Category Healthcare
    • No. of Pages 33
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Mumps - Pipeline Review, H1 2017, provides an overview of the Mumps (Infectious Disease) pipeline landscape.

    Mumps is a contagious disease that leads to painful swelling of the salivary glands. The mumps are caused by a virus. The virus is spread from person-to-person by respiratory droplets (for example, when you sneeze) or by direct contact with items that have been contaminated with infected saliva. Symptoms include fever, face pain, headache, sore throat, swelling of the temples or jaw and swelling of the parotid glands. Treatment includes pain relievers (to get relief for symptoms).

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Mumps - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Mumps (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Mumps (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Mumps and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 1, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

    Mumps (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Mumps (Infectious Disease).
    - The pipeline guide reviews pipeline therapeutics for Mumps (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Mumps (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Mumps (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Mumps (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Mumps (Infectious Disease).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Mumps (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Mumps - Overview
    Mumps - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Mumps - Therapeutics Assessment
    Assessment by Route of Administration
    Assessment by Molecule Type
    Mumps - Companies Involved in Therapeutics Development
    Beijing Minhai Biotechnology Co Ltd
    Beijing Tiantan Biological Products Co Ltd
    Daiichi Sankyo Company Ltd
    GlaxoSmithKline Plc
    Prometheon Pharma LLC
    Sinovac Biotech Ltd
    Zydus Cadila Healthcare Ltd
    Mumps - Drug Profiles
    (measles + mumps + rubella + varicella) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (measles + mumps + rubella + varicella) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (measles + mumps + rubella) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (measles + mumps + rubella) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (measles + mumps + rubella) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    mumps vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    mumps vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VN-0102 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Mumps - Dormant Projects
    Mumps - Product Development Milestones
    Featured News & Press Releases
    Jun 13, 2012: UGA researcher developing new vaccine to fight resurging mumps virus
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Mumps, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Mumps - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017
    Mumps - Pipeline by Beijing Tiantan Biological Products Co Ltd, H1 2017
    Mumps - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
    Mumps - Pipeline by GlaxoSmithKline Plc, H1 2017
    Mumps - Pipeline by Prometheon Pharma LLC, H1 2017
    Mumps - Pipeline by Sinovac Biotech Ltd, H1 2017
    Mumps - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
    Mumps - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Mumps, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Beijing Minhai Biotechnology Co Ltd
    Beijing Tiantan Biological Products Co Ltd
    Daiichi Sankyo Company Ltd
    GlaxoSmithKline Plc
    Prometheon Pharma LLC
    Sinovac Biotech Ltd
    Zydus Cadila Healthcare Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//mumps-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//mumps-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//mumps-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments